Not Yet RecruitingNot Applicable

Repolarization and Activation Mapping in Ventricular Tachycardia Ablation: the REDEMPTION Study

40 participantsStarted 2025-06-01

Plain-language summary

The aim of this study is to prospectively evaluate a novel sinus rhythm mapping strategy for ventricular tachycardia (VT) ablation based on combined ventricular repolarization and activation (depolarization) mapping (REpolarization DEpolarization Mapping, REDEEM mapping). Furthermore, gathering clinical data on VT ablation with TactiFlex is also aimed.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ventricular tachycardia ablation procedure;
✓. High density endocardial or epicardial substrate EAM performed with the multipolar mapping catheter Advisor™ HD-Grid Mapping Catheter, (Abbott Labs, Abbott Park, IL, USA) in association with the EnsiteXTM Cardiac Mapping System, (Abbott Labs, Abbott Park, IL, USA); 3) Use of TactiFlexTM ablation catheter (Abbott Labs, Abbott Park, IL, USA).

What they're measuring

Efficacy outcome

Timeframe: 1 Year

Trial details

NCT IDNCT06765746

SponsorUniversitair Ziekenhuis Brussel

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-06-01

Contact for this trial

Luigi Pannone, MD - PhD

02 477 5660 luigi.pannone@uzbrussel.be

View on ClinicalTrials.gov More Ventricular Tachycardia Ablation trials